Mitsubishi Research Institute and Astellas have agreed on a memorandum of understanding to provide drug-discovery startups in ...

The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...

Astellas Pharma (($ALPMY)) announced an update on their ongoing clinical study. Study Overview: Astellas Pharma is ...

The Japanese pharma giant is doubling down on the star solid tumor target with a new licensing deal for a phase 2 antibody drug conjugate worth up to $1.34 billion. Astellas aims for CLDN18.2 gold ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license ...

TOKYO and SUZHOU, China, May 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today ...

MELVILLE, N.Y., June 17, 2025 /PRNewswire/ -- Nikon Instruments Inc. (Nikon), a wholly owned subsidiary of Nikon Corporation, and Astellas Innovation Management LLC ("Astellas"), a wholly owned ...

Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license ...

Astellas has significant expertise in developing therapies that target CLDN18.2, including Vyloy, the first CLDN18.2-targeted therapy approved in the world. XNW27011 has the potential to address ...